Navigation Links
Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
Date:7/27/2011

SAN DIEGO, July 27, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. NV-128 is the prodrug of the Company's investigational compound and lead mitochondrial inhibitor drug candidate, NV-344. The publication, entitled "Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells," is available on the Molecular Cancer Therapeutics website and scheduled to print in the August issue of the journal. An abstract can be found at www.marshalledwardsinc.com/our-programs/scientific-publications.

"A major obstacle in the successful treatment of ovarian cancer is disease recurrence due in part to the outgrowth of chemotherapy-resistant ovarian cancer stem cells," said senior author Gil Mor, M.D., Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine. "This study shows that NV-128 can specifically target the mitochondriain patient-derived ovarian cancer stem cells to induce cell death in an otherwise chemo-resistant cell population. We believe these encouraging data provide sufficient proof of concept to warrant further study in ovarian cancer patients."

Previous studies conducted at Yale University showed that NV-128 is able to inhibit tumor growth in an ovarian cancer animal model without inducing significant toxicity, suggesting a sufficient therapeutic window that may allow compounds of this class to be safely administered to patients. Once administered, NV-128 is demethylated in vivo to NV-344, its active metabolite, which has been show
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards to Host Annual Meeting of Stockholders
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Announces Private Placement
7. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
8. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
9. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Fla. , Aug. 1, 2014 Dyadic ... whose patented and proprietary technologies are used to develop, ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... the second quarter ended June 30, 2014 after market ... a conference call that day at 5:00 p.m. Eastern ...
(Date:7/31/2014)... , July 31, 2014  According to data released ... the 2015 average monthly Medicare Part D premium is ... lower than was originally projected, the Pharmaceutical Care Management ... program continues to be a bright spot in American ... in each region and using cutting edge, cost-saving tools ...
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13
... ALLEGAN, Mich., May 10, 2011 Perrigo Company (Nasdaq: ... to settle all Hatch-Waxman litigation relating to fluticasone lotion brought ... relevant patents. Under the terms of the settlement, Perrigo can ... 22, 2012, or earlier under certain circumstances. ...
... Tenn., May 10, 2011 MedQuist Holdings Inc. (NASDAQ: ... transcription services and technology-enabled clinical documentation workflow solutions, today ... St. Joseph,s Hospital Health Center in Syracuse, New York, ... projected to achieve significant cost savings and improve efficiency ...
Cached Medicine Technology:Perrigo Announces Settlement of Cutivate Lotion Litigation 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 3
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... NV (PRWEB) August 01, 2014 ... opportunities for independent community pharmacies. At ThoughtSpot 2014, ... are equipped with practices and resources to enhance ... AmerisourceBergen leaders focused on critical issues to give ... optimize and grow. , ThoughtSpot show attendance ...
(Date:8/1/2014)... Dallas, Texas (PRWEB) August 01, 2014 ... universal health coverage and healthcare reforms are boosting ... price of medicines through discounts and increasing generic ... stood at approximately 76.7 million in 2013, having ... of 1.4%, from 2008. The implementation of the ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... importance of a nutritious lunch towards maintaining a healthy ... Commonwealth Games gold medal marathon runner// and mother of ... Dr John Tickell, and award-winning chef Michael Moore. ... to encourage Australians to make a healthy lunch a ...
... which are mainly used to prevent blocking of various arteries ... patients require other procedures// such as angioplasty or a by ... flexible nickel-titanium tubes. They are very effective in ... Researchers conducted a new study and published it in the ...
... that they are requesting patients to take a blood ... for a blood test for HIV and Hepatitis. Scripps ... nurse had failed to follow proper sterilization procedures for ... the so-called stomach-stapling operations. The instrument requires a different ...
... look into the costs of healthcare, met in Adelaide, and ... extremely high and has no system of prioritising patients. ... reason for wanting her breasts reduced has to wait just ... aesthetic reasons. Women who were in need for the surgery ...
... meet this week in Abuja, Nigeria, to review the progress ... malaria, tuberculosis. ,Five years ago the leaders had ... 15 per cent of national budgets in order to accelerate ... as other diseases. ,However progress has been dismal. ...
... carry a potential risk of suffering asthma, than compared to ... is published in the May 1 issue of Environmental Health ... 75 meters (about 82 yards) of a major road had ... in the past year than were children who lived more ...
Cached Medicine News:Health News:Celebrities Promote Healthy Lunch 2Health News:Waiting Period Of Over 10yrs For Women Needing Breast Reduction Surgery 2Health News:Review of Reversal of Spread of Diseases in Africa 2Health News:Asthma Risk Pronounced In Children Living Close to Traffic Ridden Roads 2
... EasyID is a patient identification ... cost savings by eliminating embossers, imprinters ... efficiency and workflow throughout the facility. ... patient identification and is designed to ...
The Metrologic MS9520 Voyager is a high performance single line laser bar code scanner with automatic activation and sophisticated data transmission via Metrologic proprietary CodeGate technology....
... latex-free, thermal transfer wristband for printing ... images that resist smears and abrasion ... cleaners, and blood. A time-tested and ... patron management applications. A tamper-evident VOID ...
... Durable, secure, direct thermal wristband ... entertainment venue patron admissions. Its clip ... five colors plus white for color ... Zebra printers for peak performance. Print ...
Medicine Products: